Ziopharm Oncology Inc (ZIOP.O) said its experimental cancer treatment, Zymafos, met a key goal in a mid-stage trial, driving its shares up as much as 38 percent.
Stay updated on the latest technologies and news with Biocompare's newsletters (See samples here)